Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of RP-G28 in Healthy Volunteers
NCT03563846Phase 1Completed
- Sponsor
- Ritter Pharmaceuticals
- Start
- Mar 2018
- Primary completion
- Apr 2018
- Modality
- Microbiome Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of galacto-oligosaccharides in lactose intolerance (2 arms), sponsored by Ritter Pharmaceuticals. Primary endpoint: Area under the plasma concentration-time curve from time 0 extrapolated to infinity at Day 3. Started Mar 2018; status: completed.
02
Drugs
galacto-oligosaccharides
03
Conditions
lactose intolerance
Beyond the preview
Go deeper on NCT03563846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03563846.